
The biotechnology sector is at a critical juncture, marked by the accelerated integration of artificial intelligence (AI) and innovations in personalized therapies. However, it faces significant structural challenges, notably the "patent cliff," which threatens to reduce industry revenues by $400 billion. This massive patent expiration is pushing companies to innovate rapidly to offset the revenue loss. The convergence of AI and biotechnology offers unprecedented opportunities but also raises ethical and security concerns, particularly regarding intellectual property and cyber risks.
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.